aTyr Pharma's lung disease drug misses main goal in late-stage trial-March 2024-www.financetom.com

aTyr Pharma's lung disease drug misses main goal in late-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

aTyr Pharma's lung disease drug misses main goal in late-stage trial

Sep 15, 2025 5:12 AM

Sept 15 (Reuters) - aTyr Pharma ( ATYR ) said on Monday

its experimental drug did not meet the main goal in a late-stage

study in patients with a type of lung disease known as pulmonary

sarcoidosis.

Previous page： Archer-Daniels-Midland Q2 Adjusted Earnings, Revenue Fall; Full-Year EPS Outlook Revised Next page： Google agrees $36 million fine for anti-competitive deals with Australia telcos

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Archer-Daniels-Midland Q2 Adjusted Earnings, Revenue Fall; Full-Year EPS Outlook Revised

Aug 5, 2025

07:25 AM EDT, 08/05/2025 (MT Newswires) -- Archer-Daniels-Midland ( ADM ) reported Q2 adjusted earnings Tuesday of $0.93 per diluted share, down from $1.03 a year earlier. Analysts polled by FactSet expected $0.82. Revenue for the quarter ended June 30 was $21.17 billion, compared with $22.25 billion a year earlier. Analysts surveyed by FactSet expected $22.03 billion. For 2025, the...

Google agrees $36 million fine for anti-competitive deals with Australia telcos

Aug 17, 2025

SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...

J & J Snack Foods Q3 sales rise 3.3%, beat expectations

Aug 5, 2025

Overview * J & J Snack Foods ( JJSF ) Q3 net sales rise 3.3%, beating analysts' expectations * Adjusted EPS for Q3 beats consensus * Co's operating income boosted by insurance proceeds and expense management Outlook * Company remains cautious due to consumer environment and tariff-related risks * J & J Snack Foods ( JJSF ) expects box office...

Yum! Brands Q2 Adjusted Earnings, Revenue Rise

Aug 5, 2025

07:25 AM EDT, 08/05/2025 (MT Newswires) -- Yum! Brands ( YUM ) reported Q2 adjusted earnings Tuesday of $1.44 per diluted share, compared with $1.35 a year earlier. Analysts surveyed by FactSet expected $1.46. Revenue for the quarter ended June 30 was $1.93 billion, compared with $1.76 billion a year earlier. Analysts surveyed by FactSet expected $1.94 billion. Shares of...